July 13 2021
Presentations at the European Crohn's and Colitis Organization annual meeting supported the transition to adalimumab biosimilars and provided patient acceptance data.
June 25 2021
A turning point for interchangeable biosimilars has arrived, as the first may be approved this year, but many questions about these agents have yet to be answered, according to Laura Sim, senior counsel for Amgen.
June 23 2021
Pay-for-delay settlements between drug companies are better regulated than in the past and are in danger of being overregulated, one panelist said.